NASDAQ:BIOC - Biocept Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.95 -0.03 (-3.06 %)
(As of 04/24/2019 06:23 AM ET)
Previous Close$0.98
Today's Range$0.9205 - $0.9778
52-Week Range$0.66 - $12.15
Volume1.15 million shs
Average Volume2.81 million shs
Market Capitalization$17.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.93
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.25 million
Book Value$0.66 per share

Profitability

Net Income$-24,570,000.00
Net Margins-755.80%

Miscellaneous

Employees95
Market Cap$17.92 million
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable

Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) posted its earnings results on Thursday, March, 28th. The medical research company reported ($1.43) EPS for the quarter, beating analysts' consensus estimates of ($1.50) by $0.07. The medical research company earned $0.86 million during the quarter, compared to the consensus estimate of $0.95 million. Biocept had a negative return on equity of 427.45% and a negative net margin of 755.80%. View Biocept's Earnings History.

When is Biocept's next earnings date?

Biocept is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Biocept.

What is the consensus analysts' recommendation for Biocept?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.

What are Wall Street analysts saying about Biocept stock?

Here are some recent quotes from research analysts about Biocept stock:
  • 1. Maxim Group analysts commented, "We are initiating coverage of Buy rating and $3 price target. Biocept’s Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates circulating tumor cell (CTC) analysis which differentiates the company in an increasingly ‘crowded’ liquid biopsy space." (3/26/2019)
  • 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019)

Has Biocept been receiving favorable news coverage?

Media coverage about BIOC stock has been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocept earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.

Are investors shorting Biocept?

Biocept saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 863,632 shares, an increase of 71.2% from the February 28th total of 504,596 shares. Based on an average daily volume of 2,868,031 shares, the days-to-cover ratio is presently 0.3 days. Currently, 7.5% of the shares of the company are short sold. View Biocept's Current Options Chain.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg, Director of Technology Devel.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.95.

How big of a company is Biocept?

Biocept has a market capitalization of $17.92 million and generates $3.25 million in revenue each year. The medical research company earns $-24,570,000.00 in net income (profit) each year or ($9.01) on an earnings per share basis. Biocept employs 95 workers across the globe.

What is Biocept's official website?

The official website for Biocept is http://www.biocept.com.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (NASDAQ BIOC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel